A case of COVID-19 and pneumonia returning from Macau in Taiwan: Clinical course and anti-SARS-CoV-2 IgG dynamic

Lee, Nan Yao; Li, Chia Wen; Tsai, Huey Pin; Chen, Po‐Lin; Syue, Ling Shan; Li, Ming Chi; Tsai, Chin-Shiang; Lo, Ching-Lung; Hsueh, Po-Ren; Ko, Wen Chien

doi:10.1016/j.jmii.2020.03.003

Cited by 62 publications

(58 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We included articles available up to May 1 2020 that contained data that could be used for the analyses in this study. This resulted in a final subset containing 19 peer-reviewed articles and two preprints ( Yongchen et al, 2020 ; Du et al, 2020 ; To et al, 2020 ; Wölfel et al, 2020 ; Okba et al, 2020 ; Zhao et al, 2020 ; Haveri et al, 2020 ; Xiao et al, 2020 ; Jiang et al, 2020 ; Lee et al, 2020 ; Liu et al, 2020a ; Long et al, 2020 ; Lou et al, 2020 ; Thevarajan et al, 2020 ; Xiang et al, 2020 ; Zhang et al, 2020a ; Zhou et al, 2020 ; Young et al, 2020 ; Zhang et al, 2020b ; Liu et al, 2020b ; Zhang et al, 2020c ; Adams et al, 2020 ; Zou et al, 2020 ). Note that initial article selection sample sizes are approximate due to the way in which Google Scholar reports the number of results.…”

Section: Methodsmentioning

confidence: 99%

Quantifying antibody kinetics and RNA detection during early-phase SARS-CoV-2 infection by time since symptom onset

Borremans

Gamble

Prager

et al. 2020

eLife

View full text Add to dashboard Cite

Understanding and mitigating SARS-CoV-2 transmission hinges on antibody and viral RNA data that inform exposure and shedding, but extensive variation in assays, study group demographics and laboratory protocols across published studies confounds inference of true biological patterns. Our meta-analysis leverages 3,214 datapoints from 516 individuals in 21 studies to reveal that seroconversion of both IgG and IgM occurs around 12 days post symptom onset (range 1-40), with extensive individual variation that is not significantly associated with disease severity. IgG and IgM detection probabilities increase from roughly 10% at symptom onset to 98-100% by day 22, after which IgM wanes while IgG remains reliably detectable. RNA detection probability decreases from roughly 90% to zero by day 30, and is highest in faeces and lower respiratory tract samples. Our findings provide a coherent evidence base for interpreting clinical diagnostics, and for the mathematical models and serological surveys that underpin public health policies.

show abstract

Section: Methodsmentioning

confidence: 99%

Quantifying antibody kinetics and RNA detection during early-phase SARS-CoV-2 infection by time since symptom onset

Borremans

Gamble

Prager

et al. 2020

eLife

View full text Add to dashboard Cite

show abstract

“…Further modifications of LAMP-based procedures have been reported, which can reduce the testing time with minimum equipment requirements [54,55]. To develop serological procedures, IgA and IgM have been evaluated against SARS-CoV-2 by immunofluorescence assays [56][57][58]. However, further refining of RT-PCR and the serological procedures are required to improve the sensitivity and specificity.…”

Section: Origin Transmission and Diagnosis Of Sars-cov-2mentioning

confidence: 99%

Origin, Potential Therapeutic Targets and Treatment for Coronavirus Disease (COVID-19)

et al. 2020

View full text Add to dashboard Cite

The ongoing episode of coronavirus disease 19 has imposed a serious threat to global health and the world economy. The disease has rapidly acquired a pandemic status affecting almost all populated areas of the planet. The causative agent of COVID-19 is a novel coronavirus known as SARS-CoV-2. The virus has an approximate 30 kb single-stranded positive-sense RNA genome, which is 74.5% to 99% identical to that of SARS-CoV, CoV-pangolin, and the coronavirus the from horseshoe bat. According to available information, SARS-CoV-2 is inferred to be a recombinant virus that originated from bats and was transmitted to humans, possibly using the pangolin as the intermediate host. The interaction of the SARS-CoV-2 spike protein with the human ACE2 (angiotensin-converting enzyme 2) receptor, and its subsequent cleavage by serine protease and fusion, are the main events in the pathophysiology. The serine protease inhibitors, spike protein-based vaccines, or ACE2 blockers may have therapeutic potential in the near future. At present, no vaccine is available against COVID-19. The disease is being treated with antiviral, antimalarial, anti-inflammatory, herbal medicines, and active plasma antibodies. In this context, the present review article provides a cumulative account of the recent information regarding the viral characteristics, potential therapeutic targets, treatment options, and prospective research questions.

show abstract

“…Immunoglobulin G (IgG) and immunoglobulin M (IgM) are known antibodies for monitoring humoral immune responses to infections by viruses such as SARS-CoV-2. [18][19][20][21][22][23][24] Because of their convenience and cost-efficiency, new serological assays of IgG and IgM antibodies have been recognised as a promising diagnostic tool to complement viral nucleic acid screening in the atrisk populations. 25 Of note, IgG/IgM seroconversion can be observed in many patients after their infections with SARS-CoV-2, 4,18,20,23,26 and serological responses are associated with disease severity.…”

Section: Introductionmentioning

confidence: 99%

Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)

Jiang

Wang

et al. 2020

Clin & Trans Imm

View full text Add to dashboard Cite

Objectives. Asymptomatic and symptomatic patients may transmit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but their clinical features and immune responses remain largely unclear. We aimed to characterise the clinical features and immune responses of asymptomatic and symptomatic patients infected with SARS-CoV-2. Methods. We collected clinical, laboratory and epidemiological records of patients hospitalised in a coronavirus field hospital in Wuhan. We performed qualitative detection of anti-SARS-CoV-2 immunoglobulin M (IgM) and immunoglobulin G (IgG) using archived blood samples. Results. Of 214 patients with SARS-CoV-2, 26 (12%) were asymptomatic at hospital admission and during hospitalisation. Most asymptomatic patients were ≤ 60 years (96%) and females (65%) and had few comorbidities (< 16%). Serum levels of white and red blood cells were higher in asymptomatic than in symptomatic patients (Pvalues < 0.05). During hospitalisation, IgG seroconversion was commonly observed in both asymptomatic and symptomatic patients (85% versus 94%, P-value = 0.07); in contrast, IgM seroconversion was less common in asymptomatic than in symptomatic patients (31% versus 74%, P-value < 0.001). The median time from the first virus-positive screening to IgG or IgM seroconversion was significantly shorter in asymptomatic than in symptomatic patients (median: 7 versus 14 days, P-value < 0.01). Furthermore, IgG/IgM seroconversion rates increased

show abstract

A case of COVID-19 and pneumonia returning from Macau in Taiwan: Clinical course and anti-SARS-CoV-2 IgG dynamic

Cited by 62 publications

References 4 publications

Quantifying antibody kinetics and RNA detection during early-phase SARS-CoV-2 infection by time since symptom onset

Quantifying antibody kinetics and RNA detection during early-phase SARS-CoV-2 infection by time since symptom onset

Origin, Potential Therapeutic Targets and Treatment for Coronavirus Disease (COVID-19)

Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)

Contact Info

Product

Resources

About